PAP
ADPT icon

Persistent Asset Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Persistent Asset Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,689
Closed -$92.8K – 808
2026
Q1 		$92.8K Hold
6,689
– – 0.03% 243
2025
Q4 		$109K Buy
+6,689
New +$109K 0.05% 262

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Persistent Asset Partners's ADPT Position: Q2 2026 in Review

Persistent Asset Partners sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 6,689 shares — an estimated $92.8K sold.

Persistent Asset Partners first reported a position in ADPT in Q4 2025 and held it in 2 quarters. The position peaked at $109K in Q4 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Persistent Asset Partners reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 6,689 Adaptive Biotechnologies shares in Q2 2026, an estimated $92.8K.
  • Persistent Asset Partners first reported a position in Adaptive Biotechnologies in Q4 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Adaptive Biotechnologies position peaked at $109K in Q4 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.